Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KLTONASDAQ:PMNNASDAQ:RENBNASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKLTOKlotho Neurosciences$1.60-20.0%$0.31$0.11▼$6.29$51.99M0.1821.50 million shs17.23 million shsPMNProMIS Neurosciences$0.52-0.1%$0.55$0.47▼$2.37$16.98M-0.0878,750 shs19,524 shsRENBRenovaro$0.37-3.8%$0.34$0.27▼$2.10$62.88M0.551.51 million shs1.91 million shsUNCYUnicycive Therapeutics$0.68+6.8%$0.62$0.20▼$1.10$82.20M2.011.96 million shs4.32 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKLTOKlotho Neurosciences-20.00%+680.49%+453.25%+464.57%+159,999,900.00%PMNProMIS Neurosciences-0.10%+8.68%+2.87%-32.18%-69.08%RENBRenovaro-3.77%+18.26%+10.70%-54.63%-74.45%UNCYUnicycive Therapeutics+6.82%-9.68%+22.05%+16.48%+3.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKLTOKlotho NeurosciencesN/AN/AN/AN/AN/AN/AN/AN/APMNProMIS Neurosciences2.3251 of 5 stars3.52.00.00.03.30.80.6RENBRenovaro2.284 of 5 stars0.04.00.00.03.83.30.6UNCYUnicycive Therapeutics3.5751 of 5 stars3.85.00.00.03.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKLTOKlotho Neurosciences 0.00N/AN/AN/APMNProMIS Neurosciences 3.00Buy$4.50766.22% UpsideRENBRenovaro 0.00N/AN/AN/AUNCYUnicycive Therapeutics 3.50Strong Buy$6.00780.54% UpsideCurrent Analyst Ratings BreakdownLatest PMN, RENB, KLTO, and UNCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$9.005/12/2025PMNProMIS NeurosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/21/2025UNCYUnicycive TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.004/11/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.504/1/2025PMNProMIS NeurosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/1/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $7.50(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKLTOKlotho NeurosciencesN/AN/A$1.68 per share0.95($2.16) per shareN/APMNProMIS NeurosciencesN/AN/AN/AN/A$0.20 per shareN/ARENBRenovaroN/AN/AN/AN/A$0.52 per shareN/AUNCYUnicycive Therapeutics$680K120.88N/AN/A($0.11) per share-6.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKLTOKlotho Neurosciences$1.35M-$0.36N/A∞N/AN/AN/A-25.89%N/APMNProMIS Neurosciences-$13.21M-$0.05N/AN/AN/AN/A-636.20%-130.32%8/6/2025 (Estimated)RENBRenovaro-$80.65M-$0.77N/A∞N/AN/A-61.84%-48.07%N/AUNCYUnicycive Therapeutics-$30.54M-$0.51N/AN/AN/AN/AN/A-29.88%N/ALatest PMN, RENB, KLTO, and UNCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025KLTOKlotho NeurosciencesN/A-$0.08N/A-$0.08N/AN/A5/14/2025Q1 2025UNCYUnicycive Therapeutics-$0.14-$0.05+$0.09-$0.05N/AN/A5/12/2025Q1 2025PMNProMIS Neurosciences-$0.14-$0.21-$0.07-$0.21N/AN/A3/31/2025Q4 2024KLTOKlotho NeurosciencesN/A-$0.07N/A-$0.07N/AN/A3/31/2025Q4 2024PMNProMIS Neurosciences-$0.14-$0.02+$0.12-$0.02N/AN/A3/27/2025Q4 2024UNCYUnicycive Therapeutics-$0.13-$0.26-$0.13-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKLTOKlotho NeurosciencesN/AN/AN/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/ARENBRenovaroN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKLTOKlotho NeurosciencesN/A0.160.16PMNProMIS NeurosciencesN/A9.309.30RENBRenovaroN/A0.060.08UNCYUnicycive TherapeuticsN/A3.613.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKLTOKlotho Neurosciences20.07%PMNProMIS Neurosciences50.13%RENBRenovaro71.41%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipKLTOKlotho Neurosciences26.70%PMNProMIS Neurosciences6.11%RENBRenovaro21.72%UNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKLTOKlotho NeurosciencesN/A32.49 million26.54 millionN/APMNProMIS Neurosciences532.69 million31.25 millionNot OptionableRENBRenovaro20172.12 million124.24 millionOptionableUNCYUnicycive Therapeutics9120.63 million78.78 millionNot OptionablePMN, RENB, KLTO, and UNCY HeadlinesRecent News About These CompaniesBrookline Capital Management Weighs in on UNCY Q3 EarningsJune 14 at 1:45 AM | americanbankingnews.comUNCY Q3 EPS Forecast Raised by Brookline Capital ManagementJune 12 at 7:52 AM | marketbeat.comKaplan Fox Announces an Investigation Into Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law ViolationsJune 11 at 5:14 PM | theglobeandmail.comRetail investors are Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) biggest owners and were hit after market cap dropped US$28mJune 11 at 5:14 PM | finance.yahoo.comUnicycive Shares Slide as FDA Flags Issues Related to Kidney Drug ApplicationJune 10, 2025 | marketwatch.comUnicycive Therapeutics stock tumbles after FDA flags manufacturing issuesJune 10, 2025 | investing.comUnicycive Therapeutics Addresses FDA Deficiencies in OLC NDA Process, Awaiting Final Decision by June 2025June 10, 2025 | quiverquant.comUnicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on DialysisJune 10, 2025 | globenewswire.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Drop in Short InterestJune 3, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for UNCY Q2 Earnings?May 30, 2025 | marketbeat.comQ4 Earnings Estimate for UNCY Issued By HC WainwrightMay 29, 2025 | marketbeat.comUnicycive Therapeutics' (UNCY) "Buy" Rating Reiterated at HC WainwrightMay 28, 2025 | marketbeat.comUnicycive Therapeutics CEO Shalabh Gupta to Present at Upcoming Investor ConferencesMay 22, 2025 | quiverquant.comUnicycive Therapeutics to Present at Upcoming Investor ConferencesMay 22, 2025 | globenewswire.comUnicycive Therapeutics Announces Time Change for 2025 Annual Meeting of StockholdersMay 21, 2025 | globenewswire.comQ2 Earnings Forecast for UNCY Issued By Noble FinancialMay 20, 2025 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Shares Acquired by Octagon Capital Advisors LPMay 15, 2025 | marketbeat.comUnicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | finanznachrichten.deUnicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | globenewswire.comAnalysts Expect Breakeven For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Before LongMay 7, 2025 | finance.yahoo.comGuggenheim Initiates Coverage of Unicycive Therapeutics (UNCY) with Buy RecommendationApril 22, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMN, RENB, KLTO, and UNCY Company DescriptionsKlotho Neurosciences NASDAQ:KLTO$1.60 -0.40 (-20.00%) As of 06/13/2025 04:00 PM EasternKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.ProMIS Neurosciences NASDAQ:PMN$0.52 0.00 (-0.19%) As of 06/13/2025 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Renovaro NASDAQ:RENB$0.37 -0.01 (-3.77%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.36 -0.01 (-2.55%) As of 06/13/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.Unicycive Therapeutics NASDAQ:UNCY$0.68 +0.04 (+6.82%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.68 +0.00 (+0.23%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
